Servier buys Shire's oncology unit for $2.4B in the run-up to Takeda's final buyout offer — if it makes one
If Takeda comes knocking on Shire’s door for what would be the largest acquisition in 2018, it won’t get the whole package it was angling for.
Shire announced it’s selling its oncology business to French immuno-oncology company Servier for $2.4 billion. The deal comes after Takeda expressed interest for a complete takeover, wooed analysts for support and reportedly sought loans to fund the effort — and just days ahead of the April 25 deadline for the Japanese drugmaker to make a bid.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.